- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/22 - Anxiolytics
Patent holdings for IPC class A61P 25/22
Total number of patents in this class: 2583
10-year publication summary
|
79
|
140
|
198
|
171
|
203
|
241
|
222
|
229
|
210
|
102
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Taisho Pharmaceutical Co., Ltd. | 851 |
43 |
| Takeda Pharmaceutical Company Limited | 2715 |
42 |
| F. Hoffmann-La Roche AG | 7836 |
35 |
| Hoffmann-La Roche Inc. | 3783 |
32 |
| Société des Produits Nestlé S.A. | 10107 |
26 |
| AstraZeneca AB | 2818 |
26 |
| Intra-Cellular Therapies, Inc. | 435 |
24 |
| H. Lundbeck A/S | 1231 |
23 |
| Sage Therapeutics, Inc. | 300 |
22 |
| Compass Pathfinder Limited | 118 |
20 |
| Daiichi Sankyo Company, Limited | 1893 |
19 |
| The Trustees of Columbia University in the City of New York | 3643 |
17 |
| Nippon Chemiphar Co., Ltd. | 226 |
17 |
| Sumitomo Dainippon Pharma Co., Ltd. | 211 |
17 |
| The Regents of the University of California | 20720 |
16 |
| Janssen Pharmaceutica N.V. | 3171 |
16 |
| Bionomics Limited | 85 |
16 |
| Glaxo Group Limited | 4370 |
14 |
| Terran Biosciences, Inc. | 107 |
14 |
| Bristol-myers Squibb Company | 4729 |
13 |
| Other owners | 2131 |